Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RR-M01
- Development stage
- Unknown
- Lead developer
- RocRock Biotechnology
- Modality
- CAR-Macrophages → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
RR-M01 is an autologous chimeric antigen receptor macrophage (CAR-M) cell therapy developed by RocRock Biotechnology for the treatment of HER2-positive solid tumors. The therapy involves engineering a patient's macrophages to express a chimeric antigen receptor (CAR) specific to the Human Epidermal Growth Factor Receptor 2 (HER2). Unlike CAR-T cells, CAR-M cells are designed to penetrate solid tumor tissues more effectively, where they can directly phagocytose HER2-expressing cancer cells and secrete pro-inflammatory cytokines to remodel the immunosuppressive tumor microenvironment. Additionally, these macrophages function as professional antigen-presenting cells, potentially stimulating a secondary T-cell-mediated anti-tumor response. RR-M01 is currently being evaluated in investigator-initiated trials for recurrent and refractory ovarian cancer, with preclinical development ongoing for other HER2-positive indications.
- Other names
- HER2-CAR-MHER-2-CAR-MHER 2-CAR-MSuzhou RocRock No.1 Biotechnology HER2-CAR-M
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on RR-M01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RR-M01.